Prenatal Genetic Diagnosis by Genomic Sequencing

Fetal Structural Anomalies Clinical Trial

— PrenatalSEQ  

Official title:

Prenatal Genetic Diagnosis by Genomic Sequencing: A Prospective Evaluation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03936101
• Other study ID #: AAAS2118
• Secondary ID: R01HD055651
• Status: Recruiting
• Start date: June 28, 2019
• Est. completion date: November 2023

Study information

• Verified date: October 2022
• Source: Columbia University
• Contact: Jessica L Giordano, CGC
• Phone: 516-521-5604
• Email: jlg2197[@]cumc.columbia.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is evaluating the impact of prenatal sequencing on the management of fetuses with ultrasound abnormalities. The hypothesis is that a significant subset of fetal abnormalities have a genetic cause that can be identified by sequencing and that prenatal knowledge of this information will improve prenatal care, reduce unnecessary diagnostic testing, reduce the cost of care, and improve the quality of life for both the child and the family.

Description:

Whole exome and whole genome sequencing (WGS) have expanded the ability to determine the genetic etiology of previously undiagnosed disorders. This study is a multicenter prospective cohort study to evaluate the emerging technology of sequencing for the management of fetuses with structural anomalies. The hypothesis is that a significant subset of fetal structural anomalies has a genetic etiology identifiable by sequencing and that prenatal knowledge of this information will improve perinatal care, reduce unnecessary diagnostic testing, reduce the cost of care, and improve quality of life for both the child and the family. The aims of this study are to investigate these multiple aspects of prenatal sequencing in a single study with an innovative integrated prospective design, which will permit a robust evaluation of the benefits and risks of delivering diagnostic and prognostic genetic testing results in a prenatal setting.

The study will determine, in a sequential population of pregnancies with selected fetal structural anomalies and a negative or non-causal chromosomal microarray (CMA), the frequency of pathogenic, likely pathogenic, and uncertain genomic variants identifiable by sequencing. To determine the impact of this information on clinical care, a control population of unsequenced pregnancies with similar structural anomalies will be prospectively recruited and the infants from both cohorts will be followed up to 1 year of age. This study component will evaluate differences in healthcare management and cost through discharge from hospital post-delivery, and perinatal and infant outcomes through 1 year of life. The educational, counseling and psychosocial impact of sequencing results during the prenatal period, in the nursery and through 1 year of life also will be evaluated. Since the analytical and clinical tools needed for the full translation of sequencing into care are still developing, optimization of bioinformatic tools to improve identification of pathogenic and likely pathogenic mutations associated with prenatal phenotypes of established disease genes will be investigated, as well as identification of new genes associated with presently undiagnosed fetal/neonatal phenotypes. This study will provide an in-depth evaluation of the prenatal diagnostic value of sequencing prior to its responsible introduction into practice and will provide independent data to guide its translation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1100
• Est. completion date: November 2023
• Est. primary completion date: August 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Prenatal sequencing group

1. Fetus identified by ultrasound and/or MRI with at least one of the following:

1. One or more major structural anomalies (Appendix A)

2. A nuchal translucency measurement of = 3.5 mm

3. A fetus less than 24 weeks 0 days gestation with normal anatomy and sonographically estimated fetal weight <5th %ile without maternal hypertension, type I diabetes, or other maternal disorders known to alter fetal growth.

2. Negative prenatal CMA (or those with CMA findings not related to the ultrasound finding)

3. Singleton or twin gestation

4. Gestational age less than 36 weeks, 0 days to allow for availability of sequencing results before delivery

Unsequenced Group

1. Fetus identified by ultrasound and/or MRI with at least one of the following:

1. One or more major structural anomalies (Appendix A)

2. A nuchal translucency measurement of = 3.5 mm

3. A fetus less than 24 weeks 0 days gestation with normal anatomy and sonographically estimated fetal weight <5th %ile without maternal hypertension, type I diabetes, or other maternal disorders known to alter fetal growth

2. Negative prenatal or postnatal CMA (or those with CMA findings not related to the ultrasound finding)

3. Declined prenatal sequencing

4. Singleton gestation

Exclusion Criteria:

Prenatal Sequencing Group

1. Prenatal sequencing or planned prenatal sequencing performed outside of the study, including gene panels

2. Maternal or paternal age less than 18 years old

3. Proven infectious or teratogenic cause of fetal anomaly

4. Planned termination of the pregnancy

5. Unavailable blood or saliva samples from both biologic parents prior to sequencing

6. Parental unwillingness to participate in 1 year postnatal follow-up

7. Language barrier (non-English or Spanish speaking)

8. Previous consent to the unsequenced prenatal group or enrollment in a previous pregnancy

Unsequenced Group

1. Maternal or paternal age less than 18 years old

2. Proven infectious or teratogenic cause of fetal anomaly

3. Positive prenatal NIPT screening for trisomy 21,18 or 13. Positive 22q11.2 prenatal NIPT testing with consistent ultrasound findings is also an exclusion.

4. Planned termination of the pregnancy

5. Parental unwillingness to participate in 1 year postnatal follow-up

6. Language barrier (non-English or Spanish speaking)

Related Conditions & MeSH terms

• Fetal Structural Anomalies

Intervention

Diagnostic Test:
• Prenatal Genomic Sequencing
Whole genome sequencing (which initially will be masked and reported as exome only)

Locations

Country	Name	City	State
United States	University of North Carolina Chapel Hill	Chapel Hill	North Carolina
United States	Children's Hospital, Cincinnati Medical Center	Cincinnati	Ohio
United States	Baylor College of Medicine	Houston	Texas
United States	UT Health Houston	Houston	Texas
United States	Columbia University Medical Center	New York	New York

Sponsors (10)

Lead Sponsor	Collaborator
Columbia University	Baylor College of Medicine, Broad Institute, Children's Hospital Medical Center, Cincinnati, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Oregon Health and Science University, The George Washington University Biostatistics Center, The Jackson Laboratory, The University of Texas Health Science Center, Houston, University of North Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reportable Variants	Reportable variants (defined as either Pathogenic, likely pathogenic, or VUS) identified by sequencing and deemed reportable by the Variant Adjudication Committee.	Approximately 4.5 years
Primary	Healthcare Costs	Healthcare costs from time of diagnosis of anomaly to infant discharge between sequenced and unsequenced groups.	Approximately 4.5 years
Secondary	Perinatal Outcomes by Medical Record Review	Perinatal outcomes will be compared and outcomes will be measured by: gestational age at delivery, major morbidities including length of ventilator support, sepsis, need for pressor support, need for ECMO, metabolic abnormalities (e.g., acidosis, elevated uric acid, hypo-/hyperglycemia), intraventricular hemorrhage/periventricular leukomalacia, encephalopathy, and seizure.	Approximately 4.5 years
Secondary	Death	Neonatal/infant death at time of discharge and at 12 months of age.	Approximately 4.5 years
Secondary	NICU Stay Duration	Length of initial NICU stay and number of days spent in the hospital between initial discharge and 12 months of age.	Approximately 4.5 years
Secondary	Length in centimeters	Infant length at 12 months of age.	Approximately 4.5 years
Secondary	Weight in kilograms	Infant weight at 12 months of age.	Approximately 4.5 years
Secondary	Development by Ages and Stages Questionnaire	Developmental outcomes defined by the following parameters: communication, gross motor, fine motor, problem solving and personal-social, at 12 months of age using ASQ-3. Lower scores are associated with developmental delay. Cutoffs for 12 month exam are: Communication 15.64, Gross Motor 21.49, Fine Motor 34.5, Problem Solving 27.32, Personal-Social 21.73	Approximately 4.5 years
Secondary	Anxiety by self-report questionnaire	Anxiety following result disclosure (or 8 weeks post enrollment for the unsequenced group), neonatal discharge and 12 months postpartum.	Approximately 4.5 years
Secondary	Depression/Anxiety by self-report questionnaire	Depression following result disclosure (or 8 weeks post enrollment for the unsequenced group), neonatal discharge and 12 months postpartum.	Approximately 4.5 years
Secondary	Quality of Life by self-report questionnaire	Quality of life for the patient and family at 12 months postpartum.	Approximately 4.5 years
Secondary	QALY, measured in cost per year	Incremental cost per Quality Adjusted Life Year (QALY).	Approximately 4.5 years
Secondary	Phenotypic Expansion - identification of new phenotypes associated with disease- Sequenced Group ONLY	Apparent prenatal phenotypic expansion from currently defined pediatric phenotypes.	Approximately 4.5 years
Secondary	VUS frequency and outcome- Sequenced Group ONLY	Variants of uncertain significance (VUS) that have not yet been associated with this disease phenotype.	Approximately 4.5 years
Secondary	GUS frequency and outcome- Sequenced Group ONLY	VUS subclassified as compelling variants in novel genes that are not yet disease associated (genes of uncertain clinical significance; GUS).	Approximately 4.5 years
Secondary	Digital WES - comparison of coding and non-coding results - Sequenced Group ONLY	Pathogenic, likely pathogenic and VUS variants identified by sequencing (coding and non-coding regions) compared with coding regions only (digital WES).	Approximately 4.5 years
Secondary	Proband Only Versus Trio - comparison of results between trio and proband only - Sequenced Group ONLY	Pathogenic, likely pathogenic and VUS variants identified by analysis of a proband alone compared to a proband-parent trio.	Approximately 4.5 years
Secondary	Change in Management (healthcare) as Determined by NICU physician and record review - Sequenced Group ONLY	Change in management decisions attributable to genomic results defined as changes to the patient's treatment plan or changes to the counseling of the patient/family regarding the immediate or long-term medical management.	Approximately 4.5 years
Secondary	Parental Understanding by self-report questionnaire - Sequenced Group ONLY	Accuracy of parental understanding of genetic test results.	Approximately 4.5 years
Secondary	Parental Support Needs - by self-report questionnaire - Sequenced Group ONLY	Educational/counseling and social support needs of the mother and father.	Approximately 4.5 years
Secondary	Classification Over Time (Change in the sequencing result over time) - Sequenced Group ONLY	Changes in classification of sequencing variants over time.	Approximately 4.5 years
Secondary	Turnaround Time - Sequenced Group ONLY	Turnaround time of sequencing components and how it changes over time.	Approximately 4.5 years